Identifying the genetic changes in a tumour that help match patients to targeted therapies and clinical trials.
No two cancers are exactly alike. Patients with the same diagnosis can carry different genetic changes in their tumours, and those changes often determine which treatment will work best.
Cancer genomic testing identifies these changes directly in tumour tissue. The results help oncologists, pathologists and surgical teams match patients to targeted therapies and clinical trials.
For patients and families, and for the oncologists, pathologists and surgical teams who request tumour testing.
Targeted therapies act on a specific genetic alteration in the cancer. They are most effective when that alteration is present and offer little benefit when it is absent. International oncology guidelines recommend testing for actionable alterations in many advanced solid tumours before treatment is selected.
Testing many genes in a single assay, rather than one gene at a time, conserves limited biopsy tissue and shortens the time to a complete molecular result. One panel test can answer several clinical questions from one sample.
Tests and pages for clinicians and healthcare professionals. Browse our portfolio of tests.
Targeted NGS of DNA and RNA from one tumour sample across 50 genes relevant to solid cancers, reported in 3 working days.
Tumour testing looks at changes in the cancer to guide treatment. When an inherited cancer risk is suspected, a genetic counsellor can explain what separate germline testing involves and what it may mean for relatives.
